Newly Published Phase III Data Show Novartis Drug Sandostatin® LAR Depot Reduced Risk Of Disease Progression By 66% In Advanced NET Patients
Links shared publicly online about this topic.
- 1,706total visits
Newly Published Phase III Data Show Novartis Drug Sandostatin® LAR Depot Reduced Risk Of Disease Progression By 66% In Advanced NET Patients
Data published in the journal of clinical oncology show that patients with advanced neuroendocrine tumors (net) of the midgut who were treated with sandostatin® lar depot (octreotide acetate f
View full resource at medicalnewstoday.com
Tags: Acromegaly Medication, Disease and Condition, Drug, Sandostatin, Novartis, Oncology
Most Recently Shared on October 2, 2009 at 1:01 pm By:
Newly Published Phase III Data Show Novartis Drug Sandostatin® LAR Depot Reduced Risk Of Disease Progression By.. http://bit.ly/ZG354
Also Shared By:
Phase III Data Published In Lancet Show Novartis Drug Zometa® Improves Overall Survival In Newly Diagnosed Multiple Myeloma Patients
medicalnewstoday.com — “A newly published study in the Lancet suggested that a first-line treatment regimen including Zometa® (zoledronic acid) significantly improved overall survival (OS) and progression-free surviv” View full resource at medicalnewstoday.com
Most Recently Shared on December 4, 2010 at 2:41 pm By:
Phase III Data Published In Lancet Show Novartis Drug Zometa® Improves Overall Survival In… http://goo.gl/fb/YxJCW
Advertisement
MNT Diabetes News
@mnt_diabetes
Newly Published Phase III Data Show Novartis Drug Sandostatin® LAR Depot Reduced Risk Of Disease Progression By.. http://bit.ly/ZG354
1 year ago...